The Crossover Healthcare Emerging Asia Public Fund LP (the "Fund") seeks to deliver high risk adjusted returns with low correlations
to broader markets and sector specific indices or ETFs by providing diversified regional exposure to both long and short investment
opportunities in the healthcare sector in Developed and Emerging Asian Markets (ex-China). The Fund seeks to identify and own
companies in the pharmaceutical, biotechnology, medical technology, and healthcare services industries where the investment team
believes new products and innovative strategies will allow target investments to become local market leaders and global participants,
leading to significant growth in earnings and market value. The strategy seeks to identify and sell short companies with models that
will be pressured in the changing global environment for healthcare, challenged to grow in the future, and dramatically over valued
from a competitive global perspective.